Nuvilex to Issue Positive Shareholder ...(ld support the marketing programs of ret...),Health

"Performance is the key to our success. Product performance, market performance, revenue performance, profit performance and management performance will drive Nuvilex' value, your return on investment," stated Schmieg. "Nuvilex has and continues to be successful at building outstanding products. The Company's next challenge is market performance. Market performance will be achieved by putting in place the resources, human and financial, that are needed to build brand awareness and distribution of our products. As consumers become aware of our products, revenue and profit performance will follow. Management is committed and dedicated to implementing and executing business strategies that are achievable and measurable."

The management of Nuvilex believes that the stage is set for Company's future. In collaboration with its major shareholders, Nuvilex has secured non-dilutive financing to ensure the Company has sufficient time to achieve its short-term marketing and sales goals and conclude its current business development activities -- partnership and out-licensing negotiations.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen, which promotes a healthy glucose metabolism; Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink( (R)), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with F
'/>"/>